Cancer Screening Guidelines

Evidence-based recommendations for early detection of the most common cancers

Key Points

• Screening detects cancer before symptoms appear — early-stage cancers are almost always more treatable.
• The USPSTF lowered the colorectal cancer screening start age to 45 in 2021; breast cancer screening now recommended from age 40.
• Lung cancer screening with annual low-dose CT is recommended for adults 50–80 with a ≥20 pack-year smoking history.
• Cervical cancer screening has evolved: HPV co-testing every 5 years (ages 30–65) is now preferred over Pap alone.
• Prostate cancer screening remains a shared decision-making conversation — benefits and harms must be individualized.
• High-risk individuals (strong family history, genetic syndromes) need earlier and more intensive screening than the general population.

Why Screening Matters

Cancer screening saves lives by finding disease at its most treatable stage — often before a patient has any symptoms. A patient diagnosed with localized breast cancer has a 5-year survival rate exceeding 99%; that figure drops sharply for metastatic disease. The same principle applies across cancer types. It is important to distinguish screening (testing asymptomatic people) from diagnostic testing (evaluating a person with symptoms or a known abnormality). Screening recommendations apply to average-risk individuals; anyone with symptoms should seek diagnostic evaluation regardless of age…

Breast Cancer Screening

Mammography remains the cornerstone of breast cancer screening. In 2024, the USPSTF updated its recommendation to advise biennial screening mammography starting at age 40 for average-risk women — lowering the previous start age of 50. The American Cancer Society recommends annual screening from age 45, with the option to start at 40, transitioning to biennial screening at age 55 for those who prefer it. Digital breast tomosynthesis (3D mammography) has largely replaced standard 2D mammography at most centers due to higher sensitivity, particularly in women with dense breasts, and lower…

Colorectal Cancer Screening

In 2021, the USPSTF updated its recommendation to begin colorectal cancer screening at age 45, down from 50, reflecting rising incidence in younger adults. This aligns with the American Cancer Society guideline. Screening continues through age 75 for average-risk individuals; shared decision-making governs ages 76–85. Multiple acceptable screening modalities exist: Colonoscopy every 10 years remains the gold standard — it is both diagnostic and therapeutic. CT colonography (virtual colonoscopy) every 5 years is an alternative for patients who decline or cannot undergo colonoscopy. Flexible…

Cervical Cancer Screening

Cervical cancer screening has been transformed by the recognition that virtually all cervical cancers are caused by persistent high-risk human papillomavirus (HPV) infection. Current USPSTF recommendations: Pap smear every 3 years for women ages 21–65, OR Pap smear plus HPV co-testing every 5 years for women ages 30–65, OR primary high-risk HPV testing alone every 5 years for women ages 30–65. Screening should begin at age 21 regardless of sexual history. Women under 30 are not candidates for co-testing due to high rates of transient HPV infection that would lead to unnecessary colposcopies.…

Lung Cancer Screening

Lung cancer is the leading cause of cancer mortality in the United States, and low-dose computed tomography (LDCT) is the only screening modality proven to reduce mortality. The landmark National Lung Screening Trial (NLST) demonstrated a 20% relative reduction in lung cancer mortality, and the European NELSON trial showed a 26% reduction in men. The USPSTF recommends annual LDCT for adults aged 50–80 who have a 20 pack-year smoking history and currently smoke or quit within the past 15 years. Screening should be discontinued once a person has not smoked for 15 years or develops a health…

Prostate Cancer Screening

Prostate-specific antigen (PSA) screening for prostate cancer remains one of the most debated topics in oncology due to the dual concerns of overdiagnosis (detecting clinically insignificant cancers) and overtreatment. The USPSTF (2018) assigns a grade C recommendation to PSA-based screening in men aged 55–69, indicating that the decision should be individualized based on patient values and preferences after discussing benefits and harms. The American Cancer Society and American Urological Association recommend offering PSA testing at age 50 for average risk, age 45 for men at higher risk…

Skin Cancer Screening

Melanoma and non-melanoma skin cancers (basal cell carcinoma, squamous cell carcinoma) are the most common cancers in the United States. Unlike other major cancers, no major guideline organization currently recommends routine population-wide skin cancer screening, due to insufficient evidence that it reduces mortality. However, high-risk individuals benefit from regular skin examinations. High-risk features warranting annual dermatologic exam include: personal or family history of melanoma, numerous (>50) atypical nevi, significant cumulative UV exposure or indoor tanning history,…